Jade Biosciences Inc. logo

Jade Biosciences (JBIO) stock

JBIO · Jade Biosciences Inc. · NASDAQ

$15.31+0.22 (+1.46%)today
Market cap
$1.06B
Shares out
69.2M
Open
$15.35
Prev close
$15.09
VWAP
$15.34
52-week range23% up the range
$11.62$27.70

Today $15.20 - $15.50

What is the latest news on JBIO stock?

JBIO rose 1.46% to $15.31 on Nov 20, 2026. No JBIO story in the last two days; the most recent is below.

13D/Gago
Amendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.

SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)

All JBIO news
Price$15.31+0.22 (+1.46%)
03:00 PM08:45 PM

When does Jade Biosciences report earnings?

Jade Biosciences last reported on Jun 1, 2026, the date it announced on May 29, 2026.

JBIO earnings history

Who owns the most JBIO stock?

FMR LLC was the largest reported holder of JBIO at the end of Q2 2026, with 9,126,877 shares worth $202.8 million. Next came Jupiter Topco LLC ($139.4 million) and Fairmount Funds Management LLC ($101.2 million). In all, 154 institutions reported $1.6 billion of JBIO in their 13F filings.

All JBIO fund holders

Financial highlights

Full financials
Net income, TTM
-$163.12M
Cash
$80.39M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

JBIO rankings

News · 26 weeks32+150%
2026-05-31: 92026-06-07: 12026-06-14: 12026-06-21: 42026-06-28: 12026-07-05: 12026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 52026-08-16: 02026-08-23: 02026-08-30: 12026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 22026-10-04: 02026-10-11: 02026-10-18: 12026-10-25: 12026-11-01: 12026-11-08: 32026-11-15: 12026-11-22: 0
2026-05-312026-11-22
Mix1090d
  • Other4(40%)
  • SEC Filings3(30%)
  • Earnings2(20%)
  • 13D/G1(10%)
Activity · 52 weeks8141 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Jade Biosciences Inc. (JBIO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for JBIO, including 2 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 16, 2026.

JBIO FAQ

8 questions
  • Is JBIO profitable?
    No. Jade Biosciences Inc. reported a net loss of $163.12M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does JBIO have?
    Jade Biosciences Inc. reported $80.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does JBIO stock trade?
    Jade Biosciences Inc. (JBIO) is listed on NASDAQ.
  • What sector and industry is JBIO in?
    Jade Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Jade Biosciences Inc. go public?
    Jade Biosciences Inc. (JBIO) completed its IPO in 2021.
  • What are analysts saying about JBIO?
    Across the last 8 analyst actions on Jade Biosciences Inc., there was 1 upgrade and 0 downgrades. The most recent action was from UBS: Buy with a $45.00 price target on 2026-06-15. Recent price targets range from $10.00 to $45.00.
  • What companies are similar to JBIO?
    Notable peers in the same industry include VNDA (Vanda Pharmaceuticals Inc.), TVTX (Travere Therapeutics Inc.), VERA (Vera Therapeutics Inc.). Compare JBIO side-by-side with any of them on Quantisnow.
  • How can I track JBIO on Quantisnow?
    Quantisnow aggregates Jade Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JBIO to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change